'Phenomenal' opportunity in drug market, Biomatters says
The Auckland-based company has a new product to help big pharma develop biological drugs.
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Auckland-based tech company Biomatters has designed cloud-based software to be used by biopharma companies developing biological drugs.
The 13-year-old company, which already has a genetic code data analysis tool called Geneious in the market, launches its new product Geneious Biologics next
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Yearly Premium Online Subscription
NZ$499.00 / yearly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Individual
Group membership
NBR Marketplace
Calida Smylie
Wed, 19 Apr 2017
Wed, 19 Apr 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Free News Alerts
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Free News Alerts
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
'Phenomenal' opportunity in drug market, Biomatters says
66398